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LETTERS
Increased Soluble lnterleukin-2 Receptor 
Concentrations in Patients with Insulin» 
dependent Diabetes Mellitus
The central pathogenetic event in insulin- 
dependent (Type 1) diabetes mellitus 
(IDDM) is the T-lymphocyte-mediated 
destruction of insulin-producing ß-cells. 
Antigenic stimulation of T-lymphocytes 
results in both production of interleukin-
2 (IL-2) and expression of IL-2 receptors 
(IL-2R). During the activation of T-lympho­
cytes, a 42~kD fragment of IL-2R is cleaved 
off and circulates as a soluble marker of 
lymphocyte activation (slL-2R). Several 
studies have investigated the presence of 
SIL-2R in IDDM patients, with conflicting 
results. While some studies reported 
increased concentrations,1,2 other investi­
gators have found lower levels of circulat­
ing siL-2R in IDDM patients when com­
pared with normal volunteers/ The aim 
of our study was to assess the slL-2R 
concentrations in newly diagnosed IDDM 
(ND-IDDM) and long-standing IDDM (LS- 
IDDM) patients, and compare them with 
slL-2R levels in healthy controls.
Thirteen ND-IDDM patients (7 men 
and 6 women; mean age 22 (13-23) 
years), and 14 LS-IDDM patients (8 men 
and 7 women; mean age 28 (12-37) 
years) were investigated. The ND-IDDM 
patients were investigated within 10 days 
of diagnosis, after the metabolic state was 
stabilized. The duration of diabetes in the 
LS-IDDM group was longer than 1 year, 
Serum fasting C-peptide levels were below
0.1 nmol I-1 in all patients. Sixteen healthy 
volunteers (9 men, 7 women, mean age 
23 (19-28) years) represented the control 
group. Serum s!L-2R concentrations were 
determined using a two-site enzyme 
immunoassay (Boehringer-Mannheim, 
Germany); detection lim it was 
20 pmol I"1. Values are given as mean 
±  standard deviation. Differences were 
compared using Kruskall-Wallis test and 
considered significant at p < 0 .0 5 .
The slL-2R concentrations were signifi­
cantly higher in IDDM patients when 
compared with healthy controls 
(120.4 ±61 .4  vs 81.9 ±26.2 pmol I '1, 
p = 0.0188). The s!L-2R concentrations 
were increased in both ND-IDDM and 
LS-IDDM patients when compared with 
controls, but no significant difference 
coutd be found between the two groups 
of patients (112.6 ±56.5 vs 
1277 ±66.9  pmol I“ 1, p = 0.5121). No 
correlation between slL-2R and the meta­
bolic status (glycemia and glycated 
haemoglobin) could be found.
In conclusion, slL-2R concentrations 
are Increased in patients with IDDM, and 
this is not correlated with the metabolic 
status. This is in accordance with some 
earlier studies,1'2 while being contradic­
tory with the report of Wagner et al. 
which has shown the opposite.1 The 
difference with this last study is difficult 
to explain, but differences in genetic 
background of the patients or the method 
of slL-2R assay may be the cause. slL-2R 
concentrations were higher in both ND- 
and LS-IDDM patients when compared 
with controls, arguing for a continuous 
activation of the T-cells in Type I diabetes. 
The increased in vivo cleavage of sIL- 
2R from activated lymphocytes is very 
probably the cause for the reported defec­
tive in vitro production of slL-2R by cells 
of IDDM patients.4 The higher concen­
trations of slL-2R (by shedding from IL- 
2-responsive T lymphocytes) in IDDM 
patients may represent an argument for 
the importance of IL-2 in the pathogenesis 
of Type 1 diabetes. Although several 
studies have shown that IL-2 production 
is impaired in IDDM patients,5,0 this might 
not represent the real situation at the 
tissue level. Thus, it has been recently 
shown that the Thl lymphocyte subset 
(producing high levels of IL-2 and IFN- 
gamma) actively promote diabetes in 
neonatal NOD mice,7 while autoimmune 
diabetes develops in transgenic mice 
expressing IL-2 and class I molecule H~ 
2Kb in their ß-cells/
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We Require a British Prevention of Dia­
betes Complications Trial
Diabetes results in increased risk of heart, 
renal, ophthalmic, cerebrovascular dis­
ease and neuropathy with peripheral vas­
cular disease. It is conceivable that a 
large proportion— perhaps some 80 %— 
of the associated morbidity and financial 
cost is avoidable by decreasing the rate 
of complications seen in people with 
diabetes to that of the non-diabetic popu­
lation. This is possible because people 
with diabetes are more than four times 
as likely to be admitted to hospital, and 
they stay on average almost twice as long 
as people who do not have diabetes.1 
There is evidence from the Diabetes 
Control and Complications Trial that 
micro vascular disease com plica tion-rates 
can be reduced in Type 1 diabetes.2 
However, strictly speaking, the financial 
cost of Type 1 diabetes is less important 
than Type 2 diabetes which strikes at a 
ratio of some 3 :1 people, and in older 
age groups.
A forthcoming Kings Fund report will 
publish an estimate of the annual hospital 
expenditure for diabetes at some 8 % of 
NHS expenditure, or roughly £2 b illion .1 
This disguises the less tangible costs of 
disease morbidity in terms of reduced 
quality of life, psychological ill-health, 
and decreased working productivity.
Studying a disease with the complexity 
of diabetes involves many unusual prob­
lems. For example, onset is usually insidi­
ous, the wide variety of vascular compli­
cations may only manifest themselves 
after a number of years in a state of
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